Prior Caregiver Education Improves Discharge Process for Patients Treated With Autologous HSCT
The goal of this initiative was to create a discharge process that was easier on patients and caregivers, and allowed for an earlier discharge time.
The goal of this initiative was to create a discharge process that was easier on patients and caregivers, and allowed for an earlier discharge time.
MASCC/ISOO Mucositis Guidelines Leadership Group released updated recommendations and suggestions for preventing and treating oral mucositis in patients undergoing cancer treatment.
For patients with GVHD, ruxolitinib improves efficacy outcomes compared with 9 other commonly used options.
In this phase I clinical trial, 2 different cohorts of patients with acute GVHD received subcutaneous injections of uhCG along with standard-of-care treatment.
This study separately evaluated the impact of depression/antidepressant use on the QOL and OS of cohorts of patients undergoing allogeneic or autologous HSCT.
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
Researchers explored the effect of using antibiotics commonly used to treat neutropenic fever on likelihood of aGVHD developing in younger patients who underwent HCT for acute leukemia.
Using a computational approach, researchers detected the effect of dietary changes and antibacterial therapies on gut microbiota of patients who had undergone allo-HSCT, which may be associated with adverse events such as GVHD.
This retrospective analysis compared auto-HSCT and allo-HSCT with tandem auto-HSCT and auto-allo-HSCT to determine which strategy provided better PFS and OS for patients with multiple myeloma.
In this study, complete viral clearance was achieved with cryopreserved matched VST developed against CMV, EBV, or ADV in patients who developed the viral infection after allogeneic stem cell transplantation.